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Background: The high-dose-rate (HDR) brachytherapy might be an effective tool for palliation of dysphagia. Because of some concerns 
about adverse effects due to absorbed radiation dose, it is important to estimate absorbed dose in risky organs during this treatment.
Objectives: This study aimed to measure the absorbed dose in the parotid, thyroid, and submandibular gland, eye, trachea, spinal cord, 
and manubrium of sternum in brachytherapy in an anthropomorphic phantom.
Materials and Methods: To measure radiation dose, eye, parotid, thyroid, and submandibular gland, spine, and sternum, an 
anthropomorphic phantom was considered with applicators to set thermoluminescence dosimeters (TLDs). A specific target volume 
of about 23 cm3 in the upper thoracic esophagus was considered as target, and phantom planned computed tomography (CT) for HDR 
brachytherapy, then with a micro-Selectron HDR (192Ir) remote after-loading unit.
Results: Absorbed doses were measured with calibrated TLDs and were expressed in centi-Gray (cGy). In regions far from target (≥ 16 cm) 
such as submandibular, parotid and thyroid glands, mean measured dose ranged from 1.65 to 5.5 cGy. In closer regions (≤ 16 cm), the 
absorbed dose might be as high as 113 cGy.
Conclusions: Our study showed similar depth and surface doses; in closer regions, the surface and depth doses differed significantly due 
to the role of primary radiation that had imposed a high-dose gradient and difference between the plan and measurement, which was 
more severe because of simplifications in tissue inhomogeneity, considered in TPS relative to phantom.
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1. Background
Esophageal cancer is the eighth most common cancer 
in the world and fourth common cause of death, which 
occurs often in thorax (1), with median survival of typi-
cally less than six months and 80% of mortalities related 
to progressive local disease (2). Conventional treatment 
of esophageal cancer includes surgery, chemotherapy, 
stent-placement, external radiotherapy, and brachy-
therapy. Brachytherapy is one of the main components 
of modern radiotherapy (3) in which radioactive sources 
are temporarily or permanently inserted into tumor. The 
Iridium-192 (192Ir) is the most commonly used source in 
the clinical practice because of its high specific activity 
and short half-life. Many studies have suggested that the 
high-dose-rate (HDR) brachytherapy is an effective tool 
for palliation of dysphagia (4). Patients with esophageal 
stricture could be treated initially with external radia-
tion therapy or chemotherapy and then, receive brachy-
therapy to complete treatment (5). Brachytherapy has 
been increasingly delivered at high dose-rates, with a 
dose of 12 Gy or more per hour. Dysphagia improvement 
has been reported in 50% of patients. The complication 
rate after single-dose brachytherapy is low (20%) and 
mainly includes fistula formation, mild retrosternal 
pain, and radiation esophagitis. Persistent/recurrent 
dysphagia following single-dose brachytherapy has 
been most commonly caused by tumor persistence 
(15%), tumor recurrence (35%), and benign stricture 
formation (5%) (6). Some adverse effects are observed 
with this treatment including dry and sore throat, re-
spiratory problems, thyroid disorders, and pain similar 
to heart burn; this might be due to high dose transfer, 
particularly in HDR brachytherapy. Adverse effects de-
pend mainly on the dose and type of radiation in which 
toxic dose 50 (TD50) is defined as 20 Gy for thyroid (7), 
maximum dose received by the spinal cord should not 
be more than 45 Gy (8), and mean dose to parotid and 
submandibular glands should not be more than 24.2 
and 46.9 Gy, respectively (9, 10). Dosimeter at these high-
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risk organs could prevent adverse effects and is initiated 
by transferring high dose to these organs and inhibits 
creation of secondary cancers, which included surface 
in vivo measurements on the body or in-depth mea-
surements in anatomical phantoms designed to simu-
late the structure of the human body (11, 12). Numer-
ous studies have suggested several dosimeters such as 
thermoluminescence dosimeters (TLDs), radiochromic 
film, and diode and ionization chamber (13, 14). Diode 
and ionization chamber were not very suitable because 
of their finite dimensions and TLD was more suitable 
and reliable to be used in brachytherapy and external 
radiation therapy (14). Moreover, TG-43 methods have a 
tendency to underestimate dose to bone, especially the 
ribs (15). The 192Ir radionuclide emits high-energy gam-
ma rays with energies up to 1.4 MeV that easily penetrate 
through patient’s body. Dickler et al. (16) have shown the 
need to consider OARs in the evaluation and compari-
son of brachytherapy sources. However, they have not 
considered radiation dose to organs located outside the 
treatment volume where photon energy determines 
the dose. Clinical studies evaluating the adverse effects 
caused by irradiating healthy organs are needed so that 
physicians have better understanding when HDR 192Ir 
might benefit a patient.
2. Objectives
In this study, the dose delivered to the parotid, thyroid, 
and submandibular gland, eye, trachea, spinal cord, and 
manubrium of sternum in brachytherapy were mea-
sured using TLD in an anthropomorphic phantom.
3. Materials and Methods
3.1. Brachytherapy and HDR Treatment Unit
The micro-Selectron HDR was remote after-loading 
unit, a treatment system developed by Flexitron In-
ternational. The TPS used the American Association of 
Physicists in Medicine (AAPM), Task Group 43 (TG-43) for-
malism for dose calculation, which includes different 
methods of optimization of the treatment’s dose distri-
bution such as geometrical/graphical optimization and 
adjustment of dwell positions/times. The 192Ir source in 
this unit has an active length of 3.5 mm and active diam-
eter of 0.6 mm. The source is enclosed in a cylindrical 
stainless steel capsule of external diameter 1.1 mm and 
length 5.0 mm (14, 17, 18) (Figure 1). The 48FR esophagus 
applicator with length of 50 cm and diameter of 1.6 cm 
was inserted in esophagus lumen of phantom, which 
was used to place dummy source in-place to take com-
puted tomographic (CT) scans of thorax for treatment 
planning. In this study, the prescribed dose per fraction 
was 5 Gy at 1 cm from the surface of the esophageal ap-
plicator with the treatment length including the tumor 
plus a 2 cm margin at both ends (4).
3.2. Calibration of Dosimeters
The TLDs (LiF-100, 3.1 × 3.1 × 0.9 mm square chips) were 
selected (19) and annealed before use in order to achieve 
better stability of their sensitivity and lower fading. The 
annealing was performed at 400°C for one hour and 
was followed by fast cooling and subsequent annealing 
at 80°C for 24 hours (Atash 1200 Exiton Crop, Iran). Sub-
sequently, elemental correction coefficients (ECCi) were 
calculated by exposure to a dose of 200 cGy with 6 MV 
photons and were applied to each TLD as ECCi = < R > / 
Ri where <R> was the mean signal of all dosimeters and 
Ri was the individual signal of each TLD (Harshaw TLD 
Reader, model 3500, the United States) (Figure 2). The 
calibration curve of TLDs was obtained by exposing TLDs 
to doses ranging from zero to 250 cGy in Plexiglas slab 
phantom (depth, 3 cm; distance, 97 cm).
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Figure 1. High-Dose-Rate 192Ir Brachytherapy Source Type Designs
Figure 2. Setup of Thermoluminescence Dosimeters Calibration
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3.3. Phantom Structure
The phantom used in this study was an anthropomor-
phic phantom constructed from natural bone and mix-
ture of paraffin wax with sodium chloride as impurity 
for soft tissue, with effective atomic number and elec-
tron density of 6.57 × 1023 and 3.36 × 1023 electrons/g, re-
spectively. Tissue substitutes for lungs were two spongy 
woods with similar dimensions and density to lungs. 
Several applicators were provided to locate TLD in several 
depths and an esophageal lumen was considered for en-
trance of esophagus applicator (20, 21) (Figure 3).
3.4. Phantom Dosimetric Measurements
In order to plan the phantom for considered treatment, 
CT scans were acquired from the phantom with applica-
tor placed into phantom. During CT scanning, external 
markers were used to avoid any mismatch between the 
planned and the treated phantom set up (Figure 4). All CT 
data were sent to the Flexiplan 3D TPS (Pars radiotherapy 
center, Tehran, Iran) and then the 192Ir sources were re-
motely loaded into the phantom while TLDs were placed 
at considered locations (10 on surface and six in depths) 
(Figure 4). Dwelling times and positions of the single 192Ir 
source were planned to deliver 5 Gy to the specific target 
volume with length of 4 cm and volume of 23 cm3 in the 
upper thoracic esophagus lumen. Target volume was CTV 
with 1 cm distal and proximal margins. The considered lo-
cations for TLDs were eye, right parotid (skin surface and 
1-cm depth), left parotid (skin surface and 1-cm depth), 
left submandibular, right submandibular, left thyroid 
(skin surface and 1-cm depth), and right thyroid glands 
(skin surface and 1cm depth), trachea (skin surface and 
4-cm depth), manubrium of sternum, spine (inside the 
phantom and skin surface).
4. Results
The calibration curve with its linear regression equa-
tion, which related the collected charge in TLDs to radia-
tion-absorbed dose, is shown in Figure 5.
Radiation doses received by organs at risk and organs 
near the transit rout of source in the phantom were mea-
sured with calibrated TLDs and then expressed in cGy (Ta-
ble 1). In addition, the calculated dose from TPS is shown 
in a separate column for comparison.
5. Discussion
In this study, the appropriate brachytherapy plan was 
considered to determine dwelling times and the posi-
tions of 192Ir sources. The accuracy of TPS was evaluated 
using TLD dosimeters and was compared with TPS cal-
culated values. Commercially available TPS use different 
methods to calculate clinical dose-rate distributions such 
as single-source data as tables or mathematical formulas, 
which need certain coefficients (19). There were some dif-
ferences between results of TPS and TLD measurements
Figure 3. Anthropomorphic Phantom Connected to the Flexitron High-
Dose-Rate Machine With Esophagus Applicator and Thermoluminescence 
Dosimeters Placed in Arbitrary Positions
Figure 4. Computed Tomographic Scan of Phantom With Esophagus Ap-
plicator
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Figure 5. Calibration Curve for Thermoluminescent Dosimeters
Nikoofar A et al.
Iran J Cancer Preven. 2015;8(3):e23304 www.ijcancerprevention.com
Table 1. Measured and Calculated Dose to Considered Organs in Phantom
Organ Absorbed Dose, cGy Mean Distance From Target, cm
Measured Calculated
Eye 1.65 ± 0.04 NA a > 25
Parotid
Depth 2.73 ± 0.76 2 19
Surface 2.00 ± 0.72 2 17
Submandibular 5.51 ± 0.81 4 16
Thyroid
Depth 6.16 ± 0.93 20 8
Surface 7.95 ± 1.81 17 7
Trachea
Depth 113.37 ± 0.30 134 8
Surface 6.60 ± 0.34 16 3.5
Spine
Depth 79.59 ± 2.91 100 4
Surface 9.10 ± 0.60 20.1 8
Manubrium of Sternum 10.87 ± 2.66 15.6 9.5
a  It was not available from TPS.
that might be due to the TPS calculation algorithm in 
which tissue inhomogeneity was not considered as 
existed in phantom. This problem was more severe in 
places with more primary radiation, e.g., thyroid, trachea, 
spine, and sternum, and TPS had overestimated absorbed 
dose. In other words, dose distribution around sources 
not only was depended on distance from source and its 
size, but also was related to the tissues absorption and 
scattering (22, 23). Moreover, the geometry function in 
dose calculation formalism had neglected scattering and 
attenuation. It provided an inverse square-law correction 
based on approximate model of the spatial distribution 
of activity in the source (19). In places where scattered 
radiation was dominant, the difference was negligible 
although some differences might result from TLD inherent 
limitations. The dose-rate contributions assumed that all 
tissues in and around the implant were water equivalent 
(at least 5 cm of water-equivalent material surrounded 
the point of calculation) (19). This might affect the dose 
calculation in closer regions to the source; as seen in Table 
1, the TPS overestimated the doses to thyroid, trachea, 
spine and manubrium of sternum. The severity of this 
effect was more in the vicinity of source.
In addition, our results showed that increasing distance 
from dwelling source position leaded to a rapid fall-off in 
dose. Trachea and spine were very close to the dwelling 
source position, but they received different dose; this 
might be due to high gradient as their corresponding do-
simeters were placed at slightly different sites (between 
T2 and T3 for spine and in front of T1 and T2 for trachea). 
The measured dose at parotid, thyroid and submandibu-
lar glands might be due to both transit dose and scattered 
radiation. Furthermore, in places near to the source, de-
crease in the dose might be due to inverse square law; but 
at larger distances tissue absorption caused a reduction 
in dose and scattering increased it. At larger distances, 
dose distribution was affected by both absorption and 
scattering phenomena and a deviation from the inverse 
square law might cause a deviation of about 20% in ab-
sorbed dose, depending on the source’s energy (22, 23). 
Marinello et al. (24) recommended always taking hyper-
dose sleeve, which was the volume receiving a dose equal 
to or greater than twice the reference dose, into account. 
One unavoidable problem with intraluminal brachyther-
apy was the steep gradient of dose distribution between 
the radioactive source and the surface mucosa. Narrower 
applicators (diameter, 8 mm) tended to deliver high dos-
es to the mucosa, which was associated with an increased 
risk of esophageal fistulas (25). In this study, we used 48 
FR esophagus applicator with 1.6-cm diameter, so there 
was no problem with hyperdose sleeve.
Yorozu et al. (25) have shown that increasing incidence 
of esophageal ulcers is related to the prescribed dose in 
brachytherapy, and doses more than 16 Gy lead to an im-
provement in local tumor control and significant risk of 
ulceration. Severe ulcers have commonly encountered 
when large fractions as high as 5 Gy or more, or a total 
dose of 15 Gy were employed with a narrow tube applica-
tor. In our research, prescribed dose was 5 Gy or total dose 
was 10 Gy in two fractions; therefore, it decreased prob-
ability of fistula formation.
According to our results, there was no difference be-
tween depth and surface dose in parotid and thyroid 
glands; it was only possible if absorbed dose to these 
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organs was due to scattered radiation when radiation 
source had been placed locally (20) and neglecting scat-
tering and attenuation in dose calculation and consider-
ing an inverse square-law correction (19).
This study was performed to estimate the absorbed dose 
to parotid, thyroid, and submandibular glands, spine, 
trachea, sternum, and eye. The high accuracy of this type 
of in vivo dosimetry is not always needed. Our results 
showed that sternum dose was less than the dose Uniyal 
et al. (26) obtained by film dosimetry, which could be due 
to many reasons such as length of treatment area, dwell-
ing position, dwelling time, and place of dosimeters. The 
absorbed dose to trachea was obtained from surface and 
in-depth measurements. Therefore, one could estimate 
the dose of trachea in depth from skin dosimetry, which 
was beneficial for patient dosimetry. Moreover, it could 
be used for quality control of TPS.
Intraluminal brachytherapy is a useful tool for treat-
ment of esophageal cancer with definitive and palliative 
goals. Dosimetric studies on phantoms are applicable 
and useful for training brachytherapy systems and have 
been considered as a valuable tool for QA program as 
well as verification of TPS, even for non-standard condi-
tions. Between all dosimeters, TLD is relatively easy and 
accurate in vivo measurement tool to evaluate dose de-
livery in brachytherapy systems. The results of in vivo 
measurements showed that the absorbed dose at distant 
positions were due to scattered radiation, which caused 
relatively similar depth and surface; however, in closer 
positions for defined targets, there were some effects of 
primary radiation and depth and surface doses were dif-
ferent. Some organs such as eyes and parotid, subman-
dibular, and thyroid glands received very low doses, 
which did not show major effects on patients’ quality of 
life. Other organs such as trachea, spine, and manubrium 
of sternum received approximately the same dose as was 
calculated by TPS.
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